伊立替康联合长春瑞滨二线治疗晚期食管癌的疗效分析

Irinotecan and vinorelbine as second-line therapy for advanced esophageal carcinoma

目的：探讨伊立替康联合长春瑞滨作为晚期食管癌二线治疗方案的效果。方法收集2012年1月至2014年1月本院肿瘤科以铂类或紫杉醇为基础一线化疗方案治疗后肿瘤病灶进展的患者31例为研究对象，所有患者均给予伊立替康50 mg/m2，静脉滴注，第1、8天使用；长春瑞滨25 mg/m2，溶于40 ml生理盐水静脉注射，第1、8天使用。每3周为1个化疗周期。结果31例患者完全缓解（CR）0例，部分缓解（PR）7例（22.6%），稳定（SD）10例（32.3%）、进展（PD）14例（45.2%），肿瘤反应率（CR＋PR）为22.6%，肿瘤控制率（CR＋PR＋SD）为54.8%。患者中位无进展生存期（PFS）为13周（95%CI：9～15周），中位总生存期（OS）为23周（95%CI：12～34周）。未发现患者无法耐受的药物不良反应。结论伊立替康联合长春瑞滨可作为晚期食管癌安全有效的二线治疗方案。

ObjectiveTo deifne the efifcacy of irinotecan combined with vinorelbine as second-line therapy of patients with advanced esophageal carcinoma.MethodEvaluated 31 patients treated with irinotecan combined with vinorelbine from January 2012 to January 2014, patients who had received platinum-based or paclitaxel-based treatment had been documented progressive disease. Irinotecan combined with vinorelbine were administered to each patient, irinotecan 50 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 3 weeks.Result31 patients were assessable for response. No patient got complete response （CR）. 7 cases （22.6%） were partial responses （PR）, 10 cases （32.3%） were stable diseases （SD） and 14 cases （45.2%） were progressive diseases （PD）. The overall response rate was 22.6% （7/31）, the disease control rate was 54.8% （17/31）. The median progression-free survival （PFS） was 13 weeks （95%CI： 9~15 weeks） and the median overall survival （OS） was 23 weeks （95%CI： 12~34 weeks）. No serious adverse reactions were identiifed. ConclusionIrinotecan combined with vinorelbine is a safe and effective second-line therapy for advanced esophageal carcinoma.